Needham Reiterates Buy on Immunocore Hldgs, Maintains $81 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum reiterated a Buy rating on Immunocore Holdings (NASDAQ:IMCR) and maintained an $81 price target.

May 09, 2024 | 9:45 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Gil Blum reiterated a Buy rating on Immunocore Holdings with an $81 price target.
The reiteration of a Buy rating and maintenance of an $81 price target by a reputable analyst like Gil Blum from Needham is likely to instill confidence among investors and could lead to a positive short-term impact on Immunocore Holdings' stock price. Analyst ratings, especially from well-regarded financial institutions, can significantly influence investor sentiment and stock prices.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100